These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32552055)

  • 21. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.
    Rome BN
    J Law Med Ethics; 2023; 51(S2):46-51. PubMed ID: 38433673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spread: pilot study of an undocumented source of pharmacy benefit manager revenue.
    Garis RI; Clark BE
    J Am Pharm Assoc (2003); 2004; 44(1):15-21. PubMed ID: 14965148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the claim percent gross margin earned by Texas community independent pharmacies for dual-eligible beneficiary claims before and after Medicare Part D.
    Winegar AL; Shepherd MD; Lawson KA; Richards KM
    J Am Pharm Assoc (2003); 2009; 49(5):617-22. PubMed ID: 19748868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacies receiving massive rebates from generic drug-makers.
    Silversides A
    CMAJ; 2006 Aug; 175(4):342. PubMed ID: 16908889
    [No Abstract]   [Full Text] [Related]  

  • 28. Wastage of medicines and its financial impact on the healthcare system in the Czech Republic.
    Smejkalová JKJKJKTAL
    Ceska Slov Farm; 2018 Dec; 67(5-6):192-199. PubMed ID: 30871324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
    Beall RF; Hardcastle L; Clement F; Hollis A
    Health Policy; 2019 Dec; 123(12):1251-1258. PubMed ID: 31601457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of Retail Pricing of Generic Urologic Medications in a Major US Metropolitan Area.
    Xu PJ; Barnes JM; Choe EM; Syed JR; Siddiqui SA
    Urology; 2019 Mar; 125():29-33. PubMed ID: 30170089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
    Mpanza NM; Bradley H; Laing R
    Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in drug prices at pharmacies: are prices higher in poorer areas?
    Gellad WF; Choudhry NK; Friedberg MW; Brookhart MA; Haas JS; Shrank WH
    Health Serv Res; 2009 Apr; 44(2 Pt 1):606-17. PubMed ID: 19178584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
    Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
    PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
    Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
    Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.